News & Updates

Show Multimedia Only

Evinacumab reduces LDL-C levels in homozygous FH

09 Dec 2021 by

Treatment with evinacumab, an angiopoietin-like protein 3 (ANGPTL3) inhibitor, reduces low-density lipoprotein cholesterol (LDL-C) levels in adolescents and adults with homozygous familial hypercholesterolaemia (FH), according to a study presented at AHA 2021.

Evinacumab reduces LDL-C levels in homozygous FH

09 Dec 2021

Inferior vena cava filters safely reduce pulmonary embolism risk in VTE

08 Dec 2021

The use of inferior vena cava filters appears to effectively reduce the risk of pulmonary embolism (PE) and PE-related and all-cause deaths in patients with venous thromboembolism (VTE), reports a recent meta-analysis.

Inferior vena cava filters safely reduce pulmonary embolism risk in VTE

08 Dec 2021

Air pollution responsible for thousands of deaths yearly: study

08 Dec 2021 by

Despite significant progress in controlling air pollution, it remains an urgent public health problem, according to a recent European study, which found that more than 300,000 deaths in the region could be attributed to air pollution in 2019.

Air pollution responsible for thousands of deaths yearly: study

08 Dec 2021

Thicker subcutaneous fat during pregnancy ups pre-eclampsia risk

07 Dec 2021

Higher subcutaneous adipose tissue thickness during the second trimester, measured using ultrasound, appears to increase the risk of pre-eclampsia, a recent study has found.

Thicker subcutaneous fat during pregnancy ups pre-eclampsia risk

07 Dec 2021

Pre-eclampsia/eclampsia predicts HFpEF hospitalization

06 Dec 2021

Pre-eclampsia/eclampsia is associated with a higher risk of hospitalization due to heart failure with preserved ejection fraction (HFpEF), reveals a recent study.

Pre-eclampsia/eclampsia predicts HFpEF hospitalization

06 Dec 2021

Empagliflozin beneficial and well tolerated in acute heart failure

06 Dec 2021 by

Empagliflozin provides a significant clinical benefit within 90 days and shows no safety concerns in patients hospitalized for acute heart failure (HF), according to results of the EMPULSE trial reported at the American Heart Association (AHA) Scientific Sessions 2021.

Empagliflozin beneficial and well tolerated in acute heart failure

06 Dec 2021

Interpregnancy weight gain ups HDP risk

05 Dec 2021

Weight gain in between pregnancies worsens the risk hypertensive disorders of pregnancy (HDP), a recent study has found.

Interpregnancy weight gain ups HDP risk

05 Dec 2021

High factor H-related protein 1 expression ups ACVD risk

05 Dec 2021

Elevated expression of the factor H-related protein 1 (FHR-1) seems to be a risk factor for atherosclerotic cardiovascular disease (ACVD), a recent study has found.

High factor H-related protein 1 expression ups ACVD risk

05 Dec 2021

Canagliflozin improves HF symptoms, QoL regardless of diabetes status

04 Dec 2021 by

The SGLT2i* canagliflozin significantly improves symptoms and quality of life (QoL) early on during treatment in people with heart failure (HF) due to either reduced or preserved ejection fraction (rEF or pEF), regardless of whether they have type 2 diabetes (T2D), according to the CHIEF-HF** study presented at AHA 2021.

Canagliflozin improves HF symptoms, QoL regardless of diabetes status

04 Dec 2021

Atrial fibrillation ups in-hospital mortality in patients with acute aortic syndromes

03 Dec 2021 by

In-hospital mortality, but not stroke, is greater among patients presenting with acute aortic syndromes and atrial fibrillation (AF) than those without AF, a study has shown.

Atrial fibrillation ups in-hospital mortality in patients with acute aortic syndromes

03 Dec 2021

News & Updates

Showing Cardiology articles

Showing

Specialty:

Evinacumab reduces LDL-C levels in homozygous FH

Evinacumab reduces LDL-C levels in homozygous FH

Inferior vena cava filters safely reduce pulmonary embolism risk in VTE

Inferior vena cava filters safely reduce pulmonary embolism risk in VTE

Air pollution responsible for thousands of deaths yearly: study

Air pollution responsible for thousands of deaths yearly: study

Thicker subcutaneous fat during pregnancy ups pre-eclampsia risk

Thicker subcutaneous fat during pregnancy ups pre-eclampsia risk

Pre-eclampsia/eclampsia predicts HFpEF hospitalization

Pre-eclampsia/eclampsia predicts HFpEF hospitalization

Empagliflozin beneficial and well tolerated in acute heart failure

Empagliflozin beneficial and well tolerated in acute heart failure

Interpregnancy weight gain ups HDP risk

Interpregnancy weight gain ups HDP risk

High factor H-related protein 1 expression ups ACVD risk

High factor H-related protein 1 expression ups ACVD risk

Canagliflozin improves HF symptoms, QoL regardless of diabetes status

Canagliflozin improves HF symptoms, QoL regardless of diabetes status

Atrial fibrillation ups in-hospital mortality in patients with acute aortic syndromes

Atrial fibrillation ups in-hospital mortality in patients with acute aortic syndromes